Literature DB >> 11799170

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.

Bluma G Brenner1, Jean-Pierre Routy, Marco Petrella, Daniela Moisi, Maureen Oliveira, Mervi Detorio, Bonnie Spira, Vidal Essabag, Brian Conway, Richard Lalonde, Rafick-Pierre Sekaly, Mark A Wainberg.   

Abstract

This study examines the persistence and fitness of multidrug-resistant (MDR) viruses acquired during primary human immunodeficiency virus infection (PHI). In four individuals, MDR infections persisted over the entire study period, ranging from 36 weeks to 5 years, in the absence of antiretroviral therapy. In stark contrast, identified source partners in two cases showed expected outgrowth of wild-type (WT) virus within 12 weeks of treatment interruption. In the first PHI case, triple-class MDR resulted in low plasma viremia (1.6 to 3 log copies/ml) over time compared with mean values obtained for an untreated PHI group harboring WT infections (4.1 to 4.3 log copies/ml). Increasing viremia in PHI patient 1 at week 52 was associated with the de novo emergence of a protease inhibitor-resistant variant through a recombination event involving the original MDR virus. MDR infections in two other untreated PHI patients yielded viremia levels typical of the untreated WT group. A fourth patient's MDR infection yielded low viremia (<50 to 500 copies/ml) for 5 years despite his having phenotypic resistance to all antiretroviral drugs in his treatment regimen. In two of these PHI cases, a rebound to higher levels of plasma viremia only occurred when the M184V mutation in reverse transcriptase could no longer be detected and, in a third case, nondetection of M184V was associated with an inability to isolate virus. To further evaluate the fitness of MDR variants acquired in PHI, MDR and corresponding WT viruses were isolated from index and source partners, respectively. Although MDR viral infectivity (50% tissue culture infective dose) was comparable to that observed for WT viruses, MDR infections in each case demonstrated 2-fold and 13- to 23-fold reductions in p24 antigen and reverse transcriptase enzymatic activity, respectively. In dual-infection competition assays, MDR viruses consistently demonstrated a marked replicative disadvantage compared with WT virus. These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799170      PMCID: PMC135882          DOI: 10.1128/jvi.76.4.1753-1761.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

Authors:  M Nijhuis; R Schuurman; D de Jong; J Erickson; E Gustchina; J Albert; P Schipper; S Gulnik; C A Boucher
Journal:  AIDS       Date:  1999-12-03       Impact factor: 4.177

2.  Selective vertical transmission of HIV: lamivudine-resistant maternal clone undetectable by conventional resistance testing.

Authors:  T Niehues; H Walter; G Homeff; V Wahn; B Schmidt
Journal:  AIDS       Date:  1999-12-03       Impact factor: 4.177

3.  Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

Authors:  J Durant; P Clevenbergh; P Halfon; P Delgiudice; S Porsin; P Simonet; N Montagne; C A Boucher; J M Schapiro; P Dellamonica
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

4.  Selective vertical transmission of HIV-1 antiretroviral resistance mutations.

Authors:  R C Colgrove; J Pitt; P H Chung; S L Welles; A J Japour
Journal:  AIDS       Date:  1998-12-03       Impact factor: 4.177

5.  Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.

Authors:  M D Miller; K E Anton; A S Mulato; P D Lamy; J M Cherrington
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

6.  Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.

Authors:  F M Hecht; R M Grant; C J Petropoulos; B Dillon; M A Chesney; H Tian; N S Hellmann; N I Bandrapalli; L Digilio; B Branson; J O Kahn
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

7.  Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy.

Authors:  D Batisse; M Karmochkine; A Si Mohamed; C Piketty; M D Kazatchkine; L Belec
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

8.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

Authors:  S J Little; E S Daar; R T D'Aquila; P H Keiser; E Connick; J M Whitcomb; N S Hellmann; C J Petropoulos; L Sutton; J A Pitt; E S Rosenberg; R A Koup; B D Walker; D D Richman
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

9.  Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

Authors:  J Martinez-Picado; A V Savara; L Sutton; R T D'Aquila
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 10.  Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

Authors:  M S Hirsch; B Conway; R T D'Aquila; V A Johnson; F Brun-Vézinet; B Clotet; L M Demeter; S M Hammer; D M Jacobsen; D R Kuritzkes; C Loveday; J W Mellors; S Vella; D D Richman
Journal:  JAMA       Date:  1998-06-24       Impact factor: 56.272

View more
  50 in total

1.  Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.

Authors:  Mian-Er Cong; Ae S Youngpairoj; Qi Zheng; Wutyi Aung; James Mitchell; Elizabeth Sweeney; Debra L Hanson; R Michael Hendry; Charles Dobard; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Authors:  Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.

Authors:  Marine Karchava; Wendy Pulver; Lou Smith; Sean Philpott; Timothy J Sullivan; Judith Wethers; Monica M Parker
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

4.  The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Authors:  Mian-er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

5.  Case files from Stanford University Medical Center: Drug resistance testing in previously untreated patients with HIV--knowing what to look for and choosing appropriate therapy.

Authors:  Robert W Shafer; Dong Phuong Nguyen; W Jeffrey Fessel
Journal:  MedGenMed       Date:  2006-08-07

6.  Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Authors:  Francine Bouchonnet; Elisabeth Dam; Fabrizio Mammano; Vaea de Soultrait; Gaëlle Henneré; Henri Benech; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.

Authors:  Miguel E Quiñones-Mateu; Mahlet Tadele; Mariona Parera; Antonio Mas; Jan Weber; Héctor R Rangel; Bikram Chakraborty; Bonaventura Clotet; Esteban Domingo; Luis Menéndez-Arias; Miguel A Martínez
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.

Authors:  Charlotte Hedskog; Mattias Mild; Johanna Jernberg; Ellen Sherwood; Göran Bratt; Thomas Leitner; Joakim Lundeberg; Björn Andersson; Jan Albert
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

9.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

10.  Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.

Authors:  Constance Delaugerre; Marie-Laure Chaix; Stephane Blanche; Josiane Warszawski; Dorine Cornet; Catherine Dollfus; Veronique Schneider; Marianne Burgard; Albert Faye; Laurent Mandelbrot; Roland Tubiana; Christine Rouzioux
Journal:  Retrovirology       Date:  2009-09-19       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.